Activity of oxaliplatin in patients with relapsed and refractory non-Hodgkin lymphoma.

被引：0
|
作者：
Younes, A [1 ]
McLaughlin, P [1 ]
Pro, B [1 ]
Hagemeister, FB [1 ]
Fayad, L [1 ]
Romaguera, J [1 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4722
引用
收藏
页码：296B / 296B
页数：1
相关论文
共 50 条
  • [41] High-dose sequential (HDS) chemotherapy as salvage treatment in 33 patients with refractory or relapsed non-Hodgkin's lymphoma.
    Tarella, C
    Caracciolo, D
    Gavarotti, P
    Corradini, P
    Zallio, F
    Castellino, C
    Pileri, A
    [J]. BLOOD, 1996, 88 (10) : 3881 - 3881
  • [42] Evaluation of docetaxel in the treatment of relapsed or refractory patients with intermediate and high grade non Hodgkin lymphoma.
    Romero, BS
    Chajón, E
    [J]. BLOOD, 1998, 92 (10) : 240B - 240B
  • [43] Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
    Schirmbeck, Nadine G. D.
    Mey, Ulrich J. M.
    Olivieri, Attilio
    Ko, Yon-Dschun
    Kaiser, Ulrich
    Flieger, Dimitri
    Witzens-Harig, Mathias
    Schmidt-Wolf, Ingo G. H.
    [J]. CANCER INVESTIGATION, 2016, 34 (08) : 361 - 372
  • [44] Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma
    Blum, Kristie A.
    Hamadani, Mehdi
    Phillips, Gary S.
    Lozanski, Gerard
    Johnson, Amy J.
    Lucas, David M.
    Smith, Lisa L.
    Baiocchi, Robert
    Lin, Thomas S.
    Porcu, Pierluigi
    Devine, Steven M.
    Byrd, John C.
    [J]. LEUKEMIA & LYMPHOMA, 2009, 50 (07) : 1232 - 1234
  • [45] Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma
    Blum, Kristie A.
    Hamadani, Mehdi
    Phillips, Gary S.
    Lozanski, Gerard
    Johnson, Amy J.
    Lucas, David M.
    Smith, Lisa L.
    Baiocchi, Robert
    Lin, Thomas S.
    Porcu, Pierluigi
    Devine, Steven M.
    Byrd, John C.
    [J]. LEUKEMIA & LYMPHOMA, 2009, 50 (03) : 349 - 356
  • [46] Rituximab in the treatment of patients with relapsed low-grade or follicular non-Hodgkin's lymphoma.
    Capote, FJ
    Bernabé, R
    Martin, MV
    Porta, J
    Almagro, M
    Moreno-Nogueira, JA
    Gil, JL
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S90 - S90
  • [47] Experience on Therapy with 90Y Ibritumomab Tiuxetan in Relapsed/Refractory Non-Hodgkin Lymphoma. Analysis of Outcomes
    Baringo, T.
    Giraldo, P.
    Lievano, P.
    Navarro, P.
    Arroyo, E.
    Ananos, M.
    de la Cueva, L.
    Abos, D.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S352 - S352
  • [48] Paclitaxel and topotecan in combination with rituximab as effective salvage regimen in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Canales, MA
    Sanjurjo, MJ
    Garcia-Vela, JA
    de Paz, R
    Gracia, J
    Hernandez, D
    Bustos, JG
    Hernandez-Navarro, F
    [J]. BLOOD, 2003, 102 (11) : 289B - 289B
  • [49] Efficacy and Safety of Clofarabine in Relapsed and/or Refractory Non-Hodgkin Lymphoma, Including Rituximab-Refractory Patients
    Nabhan, Chadi
    Davis, Nancy
    Bitran, Jacob D.
    Galvez, Angel
    Fried, Walter
    Tolzien, Kathy
    Foss, Susan
    Dewey, Wendy M.
    Venugopal, Parameswaran
    [J]. CANCER, 2011, 117 (07) : 1490 - 1497
  • [50] Rituximab (Rituxan) combined with ESHAP chemotherapy is highly active in relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Venugopal, P
    Gretory, SA
    Showel, J
    Shammo, J
    Enschede, S
    Larson, M
    Obrien, T
    Sokolovsky, TD
    Means, A
    [J]. BLOOD, 2004, 104 (11) : 243B - 243B
12345